Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD

Journal of Attention Disorders

Volumn 13, Issue 5, 2010, Pages 532-538

  Faraone, Stephen V ^a   Glatt, Stephen J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Alpha 2A adrenoceptor; Attention; Efficacy; Side effects; Sleep

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; GUANFACINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHEMICALLY INDUCED DISORDER; CHILD; DELAYED RELEASE FORMULATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; MALE; NAUSEA; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GUANFACINE; HUMANS; MALE; NAUSEA; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77649243562     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054709332472     Document Type: Article

References (20)

1. American Psychiatric Association [APA]. (2000 a). Diagnostic and statistical manual of mental disorders DSM-IV (4th ed.). Washington, DC: APA.
2. APA. (2000b). Diagnostic and statistical manual of mental disorders DSM-IV-TR. (4th ed.), Text revision. Washington, DC: APA, 85-102.
3. Arnsten, A.F. (2006). Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. Journal of Clinical Psychiatry, 67(suppl 8), 7-12.
4. Arnsten, A.F.T. (2001). Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex. In M. V. Solanto, A. F. T. Arnsten, & F. X. Castellanos (Eds.), Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press.
5. Arnsten, A.F., Cai, J.X., & Goldman-Rakic, P.S. (1988). The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. Journal of Neuroscience, 8, 4287-4298.
6. Biederman, J., & Faraone, S.V. (2005). Attention-deficit hyperactivity disorder. Lancet, 366, 237-248.
7. Biederman, J., Melmed, R.D., Patel, A., McBurnett, R., Konow, J., Lyne, A.et al,for the SPD503 Study Group. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121, e73-e84.
8. Carchman, S.H., Crowe, J.T., Jr., & Wright, G.J. (1987). The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. Journal of Clinical Pharmacology, 27, 762-767.
9. Chappell, P.B., Riddle, M.A., Scahill, L., Lynch, K.A., Schultz, R., Arnsten, A.et al.(1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 1140-1146.
10. Faraone, S.V., Biederman, J., Spencer, T.J., & Aleardi, M. (2006). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine, 8, 4.
11. Horrigan, J.P., & Barnhill, L.J. (1995). Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. Journal of Child and Adolescent Psychopharmacology, 5, 215-223.
12. Hunt R.D., Arnsten, A.F.T., & Asbell M.D. (1995). An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 50-54.
13. Jansson, C.C., Marjamaki, A., Luomala, K., Savola, J.M., Scheinin, M., & Akerman, K.E. (1994). Coupling of human alpha 2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. European Journal of Pharmacology, 266, 165-174.
14. Kollins, S.H., Wigal, T., Vince, B., Turnbow, J., Lopez, F.A., Brams, M.et al.(2007). Guanfacine extended release in ADHD: Safety and sleep effects. Poster presentation at the American Academy of Child and Adolescent Psychiatry 54th Annual Meeting; October 23-28, Boston, MA.
15. Newcorn, J.H., Schulz, K., Harrison, M., DeBellis, M.D., Udarbe, J.K., & Halperin, J.M. (1998). Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatric Clinics of North America, 45, 1099-22, viii.
16. Pliszka, S.R., Crismon, M.L., Hughes, C.W., Corners, C.K., Emslie, G.J., Jensen, P.S. et al., and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. (2006). The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 642-657.
17. Sallee, F., McGough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman J., for the SPD503 Study Group. (2007). Randomized, double-blind study of guanfacine extended release for 6- to 17-year-olds with attention-deficit/hyperactivity disorder (submitted). Journal of the American Academy of Child & Adolescent Psychiatry.
18. Scahill, L., Chappell, P.B., Kim, Y.S., Schultz, R.T., Katsovich, L., Shepherd, E.et al.(2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1067-1074.
19. 2A-selective compound. European Journal of Pharmacology, 202, 235-243.
20. Vuong, Q.H. (1989). Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica, 57, 307-333.